ASP2397 Is a Novel Natural Compound That Exhibits Rapid and Potent Fungicidal Activity against <i>Aspergillus</i> Species through a Specific Transporter
-
- Ikuko Nakamura
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan
-
- Keisuke Ohsumi
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan
-
- Shinobu Takeda
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan
-
- Kiyomitsu Katsumata
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan
-
- Satoru Matsumoto
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan
-
- Souichiro Akamatsu
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan
-
- Hikaru Mitori
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan
-
- Toru Nakai
- Drug Discovery Research, Astellas Pharma Inc., Ibaraki, Japan
抄録
<jats:p> Current therapies against invasive pulmonary aspergillosis (IPA) have a limited cure rate. Given that a delay in treatment initiation may be fatal, a new drug with rapid-onset and potent fungicidal activity is needed. The novel cyclic hexapeptide ASP2397 (currently known as VL-2397) exhibited antifungal activity against <jats:named-content content-type="genus-species">Aspergillus fumigatus</jats:named-content> (including azole-sensitive and azole-resistant isolates), <jats:named-content content-type="genus-species">A. terreus</jats:named-content> , and <jats:named-content content-type="genus-species">A. flavus</jats:named-content> at an MIC range of 1 to 4 μg/ml in human serum. </jats:p>
収録刊行物
-
- Antimicrobial Agents and Chemotherapy
-
Antimicrobial Agents and Chemotherapy 63 (10), 2019-10
American Society for Microbiology